Pottier P, Planchon B, Truchaud F, Pistorius M A, Furic I, Grolleau J Y
Service de Médecine Interne, CHU de Nantes, Hôtel-Dieu, 44093 Nantes Cedex 1.
J Mal Vasc. 2000 Oct;25(4):241-9.
In terms of preventive management of venous thromboembolism in medical inpatients, very large differences may be observed. Rationalization of behaviour requires the evaluation of simple and logical parameters, which takes into account both patient safety and economic considerations.
The aim of this study was to evaluate a preventive scheme including the rationalization of the indications and the use of low molecular weight heparin.
Epidemiologic investigation.
Patients hospitalized in five medical departments in the Hospital Center of Nantes, France.
The risk of venous thromboembolism was rated as high, intermediate and low. Patients with high or intermediate risk were eligible for prevention therapy (table I).
The main criterion was the occurrence during hospital stay of deep or superficial venous thrombosis of the lower limbs, pulmonary embolism, or unexplained sudden death. The screening was based on clinical features double-checked by venous doppler ultrasonography of the lower limbs and/or ventilation-perfusion lung scanning.
24,497 patients were eligible (table II), 15% were considered at risk and treated with Nadroparin, 6% had the same risk profile but were not treated and 14. 7% had low risk and no prevention. No bleeding event was reported. The incidence of venous thromboembolism was 0.75%, 1.7% and 0.14% respectively (p <0.01) (table III). This efficacy does not appear to depend on body weight or the existence of multiple risk factors observed (table IV and V).
This analysis of risk factors separates two populations with rates of incidence dramatically and significantly different. The prevention of venous thromboembolism by fixed dose of low molecular weight heparin remains justified since it reduces the risk of venous thromboembolism by a factor of 2.5.
在医疗住院患者静脉血栓栓塞的预防管理方面,可能会观察到非常大的差异。行为合理化需要评估简单且合理的参数,这要同时考虑患者安全和经济因素。
本研究的目的是评估一种预防方案,该方案包括适应证的合理化以及低分子量肝素的使用。
流行病学调查。
法国南特医院中心五个内科病房的住院患者。
将静脉血栓栓塞风险分为高、中、低三级。高风险或中风险患者 eligible for 预防治疗(表I)。
主要标准是住院期间下肢深静脉或浅静脉血栓形成、肺栓塞或不明原因猝死的发生情况。筛查基于临床特征,并通过下肢静脉多普勒超声和/或通气-灌注肺扫描进行双重检查。
24497名患者符合条件(表II),15%被认为有风险并接受那屈肝素治疗,6%有相同风险特征但未接受治疗,14.7%风险低且未进行预防。未报告出血事件。静脉血栓栓塞的发生率分别为0.75%、1.7%和0.14%(p<0.01)(表III)。这种疗效似乎不取决于体重或观察到的多种风险因素的存在(表IV和V)。
这种风险因素分析将两个发病率差异巨大且显著的人群区分开来。固定剂量低分子量肝素预防静脉血栓栓塞仍然合理,因为它将静脉血栓栓塞风险降低了2.5倍。
“eligible for”直译为“有资格获得”,这里结合语境意译为“适合进行” 。